INTRODUCTION
A major goal in the study of adaptive immune responses is to understand the developmental progression of antigen-specific T cells from naive precursors to activated effector cells and longlived memory cells. The achievement of this goal requires the ability of investigators to identify T cells with specificity to a single pMHC epitope at different moments throughout the course of an immune response. Several indirect methods are available to detect epitopespecific T cells, most of which involve the in vitro culture of bulk harvested cells with the specific antigen, followed by measurement of an aspect of T-cell responsiveness, such as cell proliferation 1 , cytokine production 2, 3 or the induction of activation markers 4, 5 . All of these approaches suffer from the limitation of relying on one of many possible T-cell functions. Therefore, epitope-specific T cells that lack that function cannot be detected.
Identification of epitope-specific T cells purely on the basis of TCR binding to the relevant pMHC solves this problem. Over the years, technologies such as flow cytometry, TCR transgenic mice and pMHC tetramers have enabled the development of powerful in vivo experimental systems that address this need 6 . In this protocol, we distill these methods into three related experimental protocols that provide a flexible framework from which to design in vivo studies of pMHC epitope-specific T cells (Fig. 1) . Two of these protocols involve the transfer of TCR transgenic T cells into histocompatible host mice, whereas the third protocol involves the detection of endogenous T-cell populations through the use of pMHC tetramers. Although many techniques are available to characterize these epitope-specific cells throughout the course of an immune response, we will focus on the use of flow cytometry in this protocol.
TCR transgenic T-cell adoptive transfer system
The first two of the three described protocols are based on the TCR transgenic T-cell adoptive transfer system developed in our laboratory 7, 8 (Fig. 1a,b) . This approach depends on TCR transgenic mice as a source of monoclonal naive T cells with a single defined epitope specificity. Naive T cells from the secondary lymphoid organs of these donor mice are injected into the bloodstream of MHCmatched host mice that express an allelic form of a surface protein, usually CD45 or CD90, which is different from the form expressed by the transferred cells. Antibodies that recognize the allelic marker, or alternatively, a unique clonotype-specific epitope on the transgenic TCR, are used to distinguish the epitope-specific donor T cells from the background of host T cells.
High-versus low-frequency adoptive transfer
A high-frequency transfer experiment involves the injection of 1 Â 10 6 -5 Â 10 6 TCR transgenic T cells per recipient mouse. Typically, about 10-15% of the transferred population (1 Â 10 5 -7 Â 10 5 cells) can be found in the secondary lymphoid organs of the recipient mouse 1 d after the transfer [9] [10] [11] . This 'parked' population is at least 1,000 times larger than the endogenous naive epitopespecific T-cell populations that have been directly measured to date, which number around 20-1,200 cells per mouse (see refs. [12] [13] [14] . Therefore, although parking a large naive population by adoptive transfer facilitates detection of the cells, it comes at the cost of creating a potentially unphysiological situation. Indeed, several studies have shown that antigen-induced activation is inefficient when the number of naive cells is very large, perhaps as a result of increased competition for pMHC 10, [15] [16] [17] [18] [19] . Thus, depending on the number of cells transferred and the dose of antigen used, conclusions drawn from adoptive transfer experiments may not accurately reflect the behavior of endogenous T cells.
Nevertheless, high-frequency transfer experiments are still very useful for applications in which high antigen doses can be used or when no low frequency alternatives are available. These applications may include experiments in which large numbers of epitopespecific cells are needed for biochemical assays, or experiments in which a high frequency of epitope-specific cells in lymphoid tissues are needed to ensure visualization during immunohistochemical 20 or two-photon intravital imaging analysis 21 . It should also be mentioned that only a handful of the estimated 10 6 endogenous epitope-specific T-cell populations in mice 22 have been measured to date [12] [13] [14] . Although the largest of these populations was 1,200 cells per mouse (see ref. 13) , it is possible that much larger populations exist in the normal repertoire. High-frequency adoptive transfer experiments may be relevant to such populations.
Concerns related to a high frequency of naive cells can be allayed by simply transferring a lower number of TCR transgenic T cells that approximates the naive precursor frequencies of known endogenous epitope-specific T cells. Considering a 10-15% cell parking efficiency [9] [10] [11] , the transfer of about 1,000 TCR transgenic T cells will generate a naive population in the range of observed endogenous populations [12] [13] [14] . However, the reliable detection of these low-frequency cells necessitates a cell enrichment step and more sophisticated flow cytometric techniques 10 , unless the cells have undergone extensive proliferation in vivo.
Endogenous T-cell enrichment
A major issue concerning the use of the adoptive transfer system is that the transferred population is monoclonal, i.e., each cell expresses the same TCR with a fixed affinity for the relevant pMHC. Therefore, issues related to the complexity of an epitopespecific T cell population, such as TCR repertoire diversity, interclonal competition and immunodominance, may not be suitably addressed by this experimental system. Rigorous investigation of such issues requires the study of epitope-specific populations within a polyclonal repertoire.
This higher experimental standard can be met through the direct study of endogenous populations of epitope-specific T cells using pMHC tetramers coupled with magnetic bead-based enrichment techniques [12] [13] [14] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] (Fig. 1c) . With this experimental strategy, the protocol is modified such that no donor T cells are transferred, and pMHC tetramers are used instead of congenic or clonotypic marker-specific antibodies to detect endogenous epitope-specific T cells. pMHC tetramers are comprised of the actual ligands recognized by the TCRs of epitope-specific T cells, so in theory they should bind all epitope-specific T cells within a tissue sample 34 . Thus, this experimental system can provide a comprehensive analysis of the entire polyclonal repertoire of epitopespecific T cells within a mouse. As with low-frequency adoptive transfer, to improve sensitivity to the point where rare naive populations can be detected, a magnetic bead-based enrichment of epitope-specific T cells and advanced flow cytometric techniques are required.
Although pMHC tetramer-based detection systems provide the opportunity to study T cells under physiological conditions, it is important to recognize the limitations of this approach. Of particular note is the possibility that there may not be an exact correspondence between the capacity of a T cell to bind to a pMHC tetramer and its capacity to become activated when confronted with the relevant pMHC on an antigen-presenting cell (APC) in the host 35 . Although cells from TCR transgenic T cell lines can be stained with pMHC tetramers with relevant specificity 12 , it has been suggested that certain T-cell clones, perhaps those with low affinity or coreceptor-dependent TCRs, are able to respond to pMHC displayed by APC but bind weakly to the relevant pMHC tetramer [36] [37] [38] [39] [40] [41] [42] [43] . In this event, pMHC tetramer staining will detect fewer epitope-specific T cells than that are able to respond. In contrast, data from our group and others 12, 13 suggest the opposite possibility. In these studies, most but not all of an epitope-specific population of naive T cells detected by a pMHC tetramer became activated in a mouse following stimulation with a high dose of the relevant antigen. Although the basis for the incomplete response is unknown, it is possible that some T cells expressed TCRs with high enough affinity to bind the pMHC tetramer but too low affinity to respond to pMHC displayed by APC. Until these uncertainties are resolved, it is best to keep in mind that pMHC staining may identify a wider or narrower range of epitope-specific T cells that can respond to the relevant pMHC epitope. In this protocol, we detail the procedures involved in the tracking of epitope-specific T cells in vivo using high-frequency adoptive transfer, low-frequency adoptive transfer or endogenous T-cell enrichment strategies (Fig. 1) . Although there is a considerable degree of overlap between these systems, each one has its unique set of advantages and disadvantages ( Table 1) , which should be carefully considered during the design of experiments. The successful use of these protocols will also require users to familiarize themselves with relevant experimental parameters of these systems, which we will discuss below.
Experimental design TCR transgenic T cells. To date, several dozen TCR transgenic mouse strains have been generated, offering a wide selection of epitope-specific CD4+ and CD8+ T-cell clones for the design of adoptive transfer experiments (http://www.jamequist.umn.edu/ Other Lab Resources.html). Many of these transgenic strains were derived from, or have been extensively backcrossed to, defined inbred strains, minimizing the chances that T cells from these mice will be rejected when transferred into recipient mice of the same background strain. The sex of the donor and recipient mice should also be matched to prevent any issues of cell rejection based on sexlinked minor antigens 44 .
As allelic exclusion of the TCRa locus is often incomplete, rearrangement and expression of an endogenous TCRa chain can occur in TCR transgenic mice, leading to the pairing of the transgenic TCRb chain to a second TCRa chain 45 . The result is that some of the T cells in a TCR transgenic mouse express TCRs with unknown pMHC specificity. This uncertainty can be avoided by crossing the TCR transgenes into mice with null mutations in either the recombination activating gene-1 (RAG-1) or recombination activating gene-2 (RAG-2) locus, the products of which are required for TCR-gene rearrangement 46, 47 . T cells from RAG-1-or RAG-2-deficient TCR transgenic mice are pure with respect to pMHC specificity, and therefore are highly recommended as a source of donor TCR transgenic T cells.
For most studies, it is not necessary to purify TCR transgenic T cells from other non-T cells ( Although we have not extensively tested different routes of injection, the intravenous route is the most logical choice for T-cell transfer because recirculating naive cells normally enter secondary lymphoid organs from the blood.
Antigens. Antigen containing the peptide of the relevant pMHC epitope may take on many different forms. The simplest form of antigen is the purified peptide itself or whole protein containing the peptide epitope sequence that can then be produced by antigen processing.
Antigenic peptide or protein can be delivered in purified form or as an expressed part of a pathogenic microbe 48, 49 , a tumor cell 50, 51 , a transplanted tissue 52, 53 or a self-tissue 54 . Often a model peptide epitope will be embedded within the sequence of a protein native to a particular pathogen to act as a surrogate antigen when no endogenous epitopes are known [55] [56] [57] .
We assume that investigators using this protocol to track epitopespecific T cells already have a well-characterized antigen delivery system in mind. The protocols described below recommend analysis of all the secondary lymphoid organs to ensure that all of the relevant epitope-specific T cells are included. The investigator may wish to modify this aspect of the protocol if the response of interest is most likely to occur in a subset of the secondary lymphoid organs, e.g., the lymph nodes draining a subcutaneous injection site.
Donor cell markers. Discrimination of donor T cells from the T cells of the recipient relies on the expression of a surface marker that is unique to the donor T cells but does not provide a target for immune rejection by the recipient mouse. A number of allelic variations of surface receptors have been bred onto TCR transgenic mice for this purpose, the most common being CD45.1 (also known as Ly5.2 or Ly5b) and CD90.1 (also known as Thy1.1). For example, OT-I TCR transgenic T cells expressing the CD45.1 allele can be adoptively transferred into C57BL/6 mice, which express the CD45.2 allele 58 . Commercially available antibodies specific to the different allelic forms of these markers can be used to identify the donor or host T-cell populations. In our experience with adoptive transfer systems involving the commonly used C57BL/6 strain as the host, the use of CD45 or CD90 as congenic markers does not appear to elicit immune rejection of the transferred cells. However, the same may not be true for other strains of mice, and care should be taken in choosing an appropriate congenic marker when designing adoptive transfer experiments.
An alternative approach to the use of congenic markers is the use of antibodies specific for a clonotypic TCR. For example, DO11.10 TCR transgenic T cells can be tracked after adoptive transfer into BALB/c mice with the use of the KJ1-26 antibody, which specifically recognizes the DO11.10 TCR 59, 60 .
The availability of multiple congenic and clonotypic markers enables the design of experiments involving the adoptive transfer of multiple distinct TCR transgenic T-cell populations. For example, CD45.1+ OT-I T cells can be cotransferred with CD90.1+ OT-II T cells into C57BL/6 mice, which are CD45.2+CD90.2+. The two donor cell populations can then be individually tracked based on their respective markers, allowing study of the interaction between CD4+ and CD8+ T cells 52 . In some unusual cases, congenic or clonotypic markers may not be sufficient to clearly identify donor T-cell populations. In such cases, antibodies to the specific TCR Vaor Vb segments used by the donor transgenic T cells can be used in addition to congenic or clonotypic antibodies to further verify their identity.
Carboxyfluorescein diacetate succinimidyl ester. The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor the proliferation history of T cells adds a powerful dimension to the adoptive transfer system 61 . TCR transgenic T cells can be labeled with the fluorescent CFSE dye before adoptive transfer. At specific time points following adoptive transfer, the relative CFSE fluorescence intensity of the cells can be used to indicate the number of divisions they have undergone. More information about the use of CFSE can be obtained from another Nature Protocols article specifically devoted to this topic 62 . An added benefit of CFSE labeling adoptively transferred T cells is that it can provide another parameter to distinguish donor from recipient T cells in cases where the donor cells have not divided extensively.
pMHC tetramers. Multimers of pMHCI or pMHCII ligands can be used to detect epitope-specific CD8+ and CD4+ T-cell populations, respectively 63, 64 . The most commonly used form of pMHC multimer is the tetramer, consisting of four identical biotinylated pMHC complexes bound to streptavidin in a tetrahedral configuration. The use of phycoerythrin (PE)-or allophycocyaninconjugated pMHC tetramers is recommended, as these reagents provide strong signals with low background while other common fluorochromes have not been as effective 65 . Moreover, magnetic beads coupled to antibodies specific for these fluorochromes are commercially available, making these fluorochromes more practical for the pMHC tetramer-based enrichment of epitope-specific T cells.
Staining with pMHCI tetramers is generally analogous to staining with antibodies; a 30-min incubation at 4 1C is usually sufficient. However, temperature can be a major factor in the staining of cells with pMHCII tetramers 35, 37, 66, 67 . For pMHCII tetramers, we recommend a standardized staining protocol of 1 h at room temperature (B22 1C).
A final pMHC tetramer concentration of 10 nM is usually adequate to stain the majority of epitope-specific T cells in a sample. Concentrations of 50 nM or higher can result in greater levels of background staining. As the optimal staining concentration is often dependent on the quality of the tetramer, a careful dose titration should be performed on each production lot of tetramer. TCR transgenic T cells specific for the relevant pMHC, if available, are quite useful for this purpose. Alternatively, T cells harvested from mice primed with the relevant antigen can be used, but an enrichment step may be necessary, as the frequency of expanded cells is expected to be low.
Once bound to T cells, pMHC tetramers are stable during most fixation and permeabilization protocols used for intracellular staining. Experiments assessing the expression of FoxP3 or intracellular cytokines in tetramer-stained T cells have been successfully performed by our group (J.J.M., M.P., A.J.P., J.B.M., T.Z. and M.K.J., unpublished data) and others 68 . Enrichment of rare epitope-specific T cells. The enrichment of rare epitope-specific T cells in mice is accomplished through a magnetic bead-based procedure that results in about a 100-fold increase in the frequency of the target population 10, 12 . Therefore, all of the epitope-specific T cells within the B2 Â 10 8 total nucleated cells harvested from the peripheral lymph nodes and spleen of a mouse can be concentrated into a sample containing only about 5 Â 10 5 -3 Â 10 6 total cells, which can be analyzed in its entirety on a flow cytometer. This allows for the comprehensive sampling of epitope-specific T cells in individual mice. Using TCR transgenic T cells as positive and negative controls, we have determined a limit of detection at about five epitope-specific T cells per mouse (see refs. 10, 12) .
For the enrichment of transferred TCR transgenic T cells, the cell sample containing the TCR transgenic T cells is stained with a biotinylated antibody specific for the congenic or clonotypic marker expressed by these cells 10 . The antibody-labeled cells are then further labeled with magnetic microbeads conjugated to streptavidin. The cell sample is then passed over a magnetized column, to which the microbead-coated T cells bind. The magnetic field is then removed from the column, and the enriched cells are eluted.
Enrichment can also be performed with fluorochromeconjugated primary antibodies and antifluorochrome-conjugated magnetic microbeads as alternative reagents. Indeed, the enrichment of rare endogenous epitope-specific T cells is performed using fluorochrome-conjugated pMHC tetramers as the primary staining reagent, followed by corresponding antifluorochrome-conjugated magnetic microbeads 12 . The use of multiple fluorochromes allows for the simultaneous enrichment of multiple populations of transferred or endogenous epitope-specific T cells from a single sample.
The efficiency of positive selection by the magnetic column decreases with increased number of magnetically labeled target cells. Therefore, for samples containing very large numbers of epitope-specific cells, it is advisable to also analyze the unbound fraction. The number of epitope-specific cells calculated in this fraction can be added to the number calculated in the enriched bound fraction to give the total number of cells for the entire sample. Alternatively, the enrichment step may be omitted entirely if the frequency of epitope-specific T cells in the mouse is known to be very large, as may be the case at the peak of a CD8+ T-cell response to an infection 69, 70 .
Flow cytometry.
When large numbers of TCR transgenic T cells are injected, the transferred cells will be numerous enough in the secondary lymphoid organs of the host to be detected by conventional flow cytometry. The use of just two identifying parameters, usually CD4 (or CD8) and the congenic (or clonotypic) marker, allows for unambiguous detection of the donor T cells from a collection of just 100,000 total events, or about 1/ 2,000th of the total nucleated cells harvested from the peripheral lymphoid organs of a mouse. Thus, a simple flow cytometer able to analyze two fluorochromes would suffice for many experiments.
However, a more sophisticated flow cytometric analysis is required when enrichment techniques are used to detect small target populations. During both antibody and pMHC tetramerbased cell enrichment schemes, a considerable number of 'sticky' nontarget cells are also enriched in the final bound fraction of the sample. Many of these cells are highly autofluorescent. In addition, detection of low-frequency T-cell populations requires that most, if not all, of the roughly 5 Â 10 5 -3 Â 10 6 cells in the bound fraction of the sample be analyzed by the flow cytometer. Together, these aspects of cell enrichment result in high levels of background noise that prevent effective donor T-cell detection with simple two-or even four-color analysis.
To overcome these background issues, analysis should be performed on an advanced flow cytometer, such as the LSR, LSRII or FACS Canto models from BD Immunocytometry Systems that are able to analyze at least six different fluorochromes. Our protocol includes multiple levels of inclusion and exclusion gating strategies to minimize background and focus critical evaluation on genuine T-cell events. At first, a side-scatter area versus width plot is used to identify cell aggregates, which are gated out of the analysis. The remaining single-cell events are then analyzed on a plot of non-T cell lineage (so-called dump) markers (B220 for B cells, CD11b and F4/80 for macrophages and CD11c for dendritic cells) versus CD3. This allows for putative T-cell events to be gated away from most other cell types, including the highly autofluorescent cells that reside along the center diagonal of the plot, as well as cells that nonspecifically bind to antibodies. The gated CD3+ T-cell events are then plotted for CD8 versus CD4 expression, which allows for the selection of the desired subpopulation and also provides another chance to gate cells away from any remaining autofluorescent events along the diagonal of the plot. Finally, CD44 is used as a marker to distinguish antigen-experienced T cells 71 . We have outlined a sixcolor basic staining panel that has been optimized for use with our protocols. Remaining available fluorescent channels may be used for additional phenotypic T-cell markers, but any new setup should be tested carefully first for fluorochrome compatibility.
Some of the commercially available antibodies specific for CD45 and CD90 alleles can stain cells with such high intensity that they cause fluorescence spillover that cannot be corrected with compensation settings on the flow cytometer. Therefore, we recommend titrating the dose of these antibodies, as well as fluorochrome-conjugated streptavidin used as a secondary staining reagent, so that positive and negative cell populations can be easily distinguished from each other without excessive amounts of fluorescent signal.
Owing to the presence of both low-and high-affinity T cells within most polyclonal T-cell populations, pMHC tetramers staining usually produces a wide range of fluorescence intensities 72 . Therefore, the discrimination of epitope-specific T cells from background can be more challenging when staining with tetramer than with congenic marker antibodies. The fair placement of gates to identify tetramer-positive events should be determined through the use of relevant negative control samples. When analyzing epitope-specific CD4+ T cells with pMHCII tetramers, CD8+-gated events from the same sample can be used as an internal negative control on which to set a tetramer-positive gate. Similarly, CD4+-gated events can be used to help in setting gates for pMHCI tetramer-positive CD8+ T cells. In addition, T cells from irrelevant TCR transgenic mice can be used as additional negative controls, provided they are processed and stained in the same experiment 12 .
Cell counting. To calculate absolute numbers of epitope-specific T cells in a sample, the total number of all cells in the sample must . PE-or allophycocyanin-conjugated pMHC tetramer (produced by the investigator, obtained from the NIH Tetramer Core facility or purchased from a commercial source) m CRITICAL The stability of pMHC tetramers can vary greatly depending on their design and construction. However, to best avoid any potential issues regarding their stability, they should be stored at 4 1C in the dark.
. Streptavidin-conjugated magnetic microbeads (Miltenyi Biotec, cat. no.
130-048-101)
. 3| Remove the spleen and as many easily accessible lymph nodes as possible. These should include at least the inguinal, axillary, brachial, cervical and mesenteric lymph nodes. Place them on top of the cell strainer in the Petri dish.
4| Using the plunger end of a 1-ml syringe, mash the lymphoid tissue over the cell strainer to liberate lymphocytes. Transfer the cells and the media that have passed through the cell strainer into a 15-ml polypropylene centrifuge tube. Rinse the cell strainer with another 2 ml of ice-cold cEHAA and add to the same tube.
5| Add ice-cold cEHAA to a final volume of 15 ml and centrifuge the tube for 5 min at 300g and 4 1C.
6|
Aspirate the supernatant and resuspend the cell pellet in 2 ml of fresh ice-cold cEHAA. Keep on ice. m CRITICAL STEP To maximize cell viability, try to minimize the amount of time taken to harvest and analyze the donor cells before adoptive transfer. This will result in higher seeding efficiencies in the recipient.
Calculate the concentration of TCR transgenic T cells 7| Transfer 5 ml of cells to a 5-ml FACS tube containing 200 ml of counting beads (at 200,000 beads ml À1 ) for later use in
Step 12.
8| Transfer 48 ml of cells to a 5-ml FACS tube for staining. Add 50 ml of ice-cold Fc block, 1 ml of anti-CD4-PE and 1 ml of anti-CD90.1-allophycocyanin (antibodies from 0.2 mg ml À1 stocks). Vortex and incubate for 30 min at 4 1C.
9| Add 5 ml of ice-cold sorter buffer and centrifuge for 5 min at 300g and 4 1C.
10|
Resuspend the cell pellet in 0.5 ml of ice-cold sorter buffer.
11| Analyze the sample on a flow cytometer, collecting 10,000 total events. Determine the percentage of cells that are TCR transgenic T cells, as identified by lymphoid forward-and side-scatter profile and costaining for CD4 and CD90.1 (Fig. 2a) .
? TROUBLESHOOTING 12| Vortex the counting beads sample (Step 7) well and immediately analyze on the flow cytometer using the same settings as for the previous stained sample, collecting 10,000 total events (Fig. 2b) .
? TROUBLESHOOTING 13| Calculate the total number of TCR transgenic T cells in the sample according to the equations described in Boxes 1 and 2.
Adoptive transfer of TCR transgenic T cells 14| If desired, label the cells with CFSE to track the cell division history 62 (see INTRODUCTION).
15| Centrifuge the cell sample for 5 min at 300g and 4 1C.
16| Aspirate the supernatant. Resuspend the cell pellet with room-temperature PBS to a concentration such that 0.3 ml will contain the desired number of TCR transgenic cells to be transferred. Note that only about 10-15% of the transferred cells will park in the recipient. m CRITICAL STEP Room-temperature PBS should be used, as intravenous injection of cold PBS could harm the recipient mouse. Representative results show 10,000 total collected events. In a parallel cell-counting analysis, a total of 10,000 events was collected from a mixture of 200 ml of counting beads (200,000 ml À1 ) and 5 ml of cell sample. The number of cell events in the analysis is equal to the number of total collected events minus the number of events in the counting beads gate. 19| Administer antigen to the mouse at least 1 d after the adoptive transfer (see INTRODUCTION for more information). m CRITICAL STEP The transferred naive cells survive with a half-life of at least 10 d, so it is not necessary to introduce antigen immediately. A 1-d interval between the transfer of cells and priming with antigen maximizes the number of transferred cells while still allowing sufficient time for them to seed the secondary lymphoid organs. m CRITICAL STEP To illustrate the sensitivity of epitope-specific T cell detection by these protocols, the examples depicted in this article involve mice which did not receive any antigen.
Harvest and enrichment of epitope-specific T cells 20| Repeat Steps 1-5 for each recipient mouse to be analyzed. There is no further need for aseptic conditions. m CRITICAL STEP Begin the protocol here for analysis of endogenous T cells in mice that did not receive TCR transgenic T cells. 
BOX 2 | CALCULATION OF EPITOPE-SPECIFIC T-CELL NUMBERS
To calculate the total number of epitope-specific T cells within a sample, determine the total number of all cells in the sample (see Box 1), and then successively multiply by the proportion of cells in each gate that defines the epitope-specific T-cell population.
For the example shown in Figure 2 
25|
Aspirate and resuspend the cell pellet with ice-cold sorter buffer to a volume of 200 ml. For antibody-labeled cells, add 50 ml of streptavidin-conjugated magnetic microbeads. For tetramer-labeled cells, add 50 ml of anti-PE or anti-allophycocyanin conjugated magnetic microbeads.
26| Incubate for 30 min at 4 1C.
27| Add ice-cold sorter buffer to a volume of 15 ml and centrifuge the tube for 5 min at 300g and 4 1C.
28| During the centrifugation described in
Step 27, set up a Miltenyi LS column on a MidiMACS magnet and prerinse with 3 ml of ice-cold sorter buffer (discard flow-through). Place a new 15-ml centrifuge tube under the column.
29|
Resuspend the cell pellet in 3 ml of ice-cold sorter buffer and add the cells through a nylon cell strainer onto the top of the column, collecting the unbound fraction into the tube placed underneath.
30| Rinse the original sample tube with 3 ml of ice-cold sorter buffer and add to the column, rinsing the cell strainer in the process. Discard the cell strainer. Add two more washes of 3 ml each to the column for a total of three 3-ml washes. Continue collecting the flow-through into the same collection tube (for unbound material).
31| Remove the column from the magnet and place on top of a new 15-ml centrifuge tube. Add 5 ml of ice-cold sorter buffer and force the buffer through in one smooth motion with the plunger. Discard the column and plunger.
32| Centrifuge the bound and unbound collection tubes for 5 min at 300g and 4 1C.
33|
Carefully aspirate all but about 50 ml of the buffer from the bound fraction tube. Resuspend the pellet to exactly 95 ml with ice-cold Fc block. Vortex the tube after resuspending the pellet to dislodge cells adhering to the sides of the tube near the bottom. Aspirate the buffer from the unbound fraction tube and resuspend to a final volume of 2 ml with ice-cold Fc block. m CRITICAL STEP The resulting cell pellet from the bound fraction will be very small and extra care should be taken to avoid cell loss during the aspiration of the supernatant. When aspirating, be sure to remove all droplets of the buffer from the sides of the tube to avoid any unwanted changes in the resuspended volume of cells.
Analysis of epitope-specific T cells by flow cytometry 34| For each sample, remove 5 ml and mix with 200 ml of counting beads (at 200,000 beads ml À1 ) in a 5-ml FACS tube. Set aside at 4 1C for later analysis (Step 42).
35| Stain each sample using option A for unenriched samples from high-frequency adoptive transfer experiments (Fig. 3) , option B for antibody-enriched samples from low-frequency adoptive transfer experiments (Fig. 4) or option C for pMHC tetramer-enriched samples from endogenous T-cell experiments (Fig. 5) . m CRITICAL STEP To minimize compensation issues, avoid the use of tandem dyes whenever possible. We recommend the following basic fluorochrome setups: (A) For unenriched samples from high-frequency adoptive transfer experiments (i) Create a mastermix cocktail of antibodies described in the table below. For two-color staining analysis, include only the CD4 and CD90.1 antibodies. Note that the final concentrations of antibody generally correspond to a 1:100 dilution of the stock concentrations. (ii) For the bound fraction of cells, add one dose of antibody cocktail directly to the whole 90-ml sample and vortex. (ii) For the bound fraction of cells, add one dose of antibody cocktail directly to the whole 90-ml sample and vortex. For the unbound fraction (if applicable), transfer 90 ml of cells to a 5-ml FACS tube, add one dose of antibody cocktail and vortex. Incubate for 30 min at 4 1C. m CRITICAL STEP When staining cells previously labeled with pMHC tetramers, avoid the use of biotinylated antibodies, as the structure of pMHC tetramers involves biotin-streptavidin linkages.
36| Prepare a set of single-stain compensation controls for calibration of the flow cytometer. For each fluorochrome to be used, set up a 5-ml FACS tube containing 99 ml of fresh mouse spleen or lymph node cells plus 1 ml of anti-CD4 antibody conjugated to that fluorochrome. In addition, set up an unstained cell sample. m CRITICAL STEP Anti-CD4 antibody is a good choice for compensation samples because many fluorochrome conjugates are available and its staining intensity is often equal to or greater than the staining intensity of the actual antibody that will be used in that color. Compensation can also be set on tubes single-stained with each actual antibody used in the experiment. However, this is not always feasible because the target population is sometimes too small to set an effective compensation gate on.
37| Incubate for 30 min at 4 1C.
38| Add ice-cold sorter buffer to a final volume of 5 ml for all samples and centrifuge the tubes for 5 min at 300g and 4 1C. another 0.25-ml ice-cold sorter buffer and pool this with the other cells in the FACS microtube. Place the microtube inside a regular 5-ml FACS tube.
40| Set up and calibrate the flow cytometer using the single-stained compensation controls. Include side-scatter width as a selected parameter for collection. ? TROUBLESHOOTING 41| Analyze the samples. For unenriched samples, collect 100,000 total events. For the unbound fractions of enriched samples, collect 500,000-1,000,000 total events. For the bound fractions of enriched samples, collect as many events as possible, up to a maximum of 2,000,000 total events. m CRITICAL STEP Try to avoid running the sample completely dry, as air bubbles may become included as part of your saved events. When the sample is almost entirely depleted, you can stop the acquisition, add more sorter buffer to the remaining volume and restart the acquisition to maximize the collection of cells in the sample. Maintain acquisition rates at about 3,000 events s À1 or less to avoid high abort rates and altered side-scatter profiles. ? TROUBLESHOOTING 44| Analyze the data from Step 42 using FlowJo software (Figs. 3c-5c ). Plot side scatter versus forward scatter and set a gate defining the population of counting beads in each sample.
45| Calculate the total number of epitope-specific T cells in the sample according to the equations described in Boxes 1 and 2.
TIMING
It takes B2 h to isolate and quantify TCR transgenic T cells from a mouse. Injection of these cells into recipient mice should require about 15 min for 1-4 mice but may take longer depending on the technical skill of the operator. Therefore, the entire adoptive transfer procedure should take about 2-3 h.
Adoptively transferred cells are usually given 1 d to seed the lymphoid organs before the mouse is primed with antigen. Effector cell studies are usually conducted within the first 1-2 weeks after priming, and memory studies cover any period of time after that.
Isolating cells from a comprehensive set of peripheral lymphoid organs takes about 15 min per mouse. Cell enrichment and staining takes about 3-4 h. The initial compensation setup of the flow cytometer takes about 30 min, and the acquisition of each sample requires about 15 min. Therefore, the analysis part of a medium-sized experiment of four samples should take about 6 h.
Ideally, all of the steps should be performed continuously and as quickly as possible, as any increases in cell death will lead to concomitant increases in background staining. However, if necessary, the best place to stop would be at a point after the harvested tissues have been processed into single-cell suspensions but before they have been stained with any reagents.
Although not advisable, cell suspensions can be kept on ice, preferably in cEHAA media, for several hours before analysis. Some of the incubation periods (antibodies, magnetic beads) can be extended with minimal effects, but room-temperature tetramer incubation periods should be adhered to rigidly. As a last resort, stained cells may be fixed with formaldehyde or paraformaldehyde and analyzed on the flow cytometer 1 d later.
? TROUBLESHOOTING Troubleshooting advice can be found in Table 2 . 
ANTICIPATED RESULTS
The total yield of TCR transgenic T cells from a TCR transgenic mouse can vary quite widely depending on the transgenic strain. In our experience, roughly 10 7 -10 8 TCR transgenic T cells can be harvested from the spleen and most lymph nodes of a TCR transgenic mouse. In general, less TCR transgenic T cells are present in TCR transgenic mice that are bred onto a RAG-1-or RAG-2-deficient background. These yields usually range from around 10 6 to 5 Â 10 7 cells per mouse.
The overall goal of these methods is to provide an assay with the sensitivity to reliably distinguish epitope-specific T cells from a background of other T cells. In the high-frequency adoptive transfer method, the frequency of donor T cells in the sample is great enough that the analysis of just 100,000 total events on the flow cytometer yields a readily identifiable population of donor T-cell events (Fig. 3) . The donor T cells can be seen using a simple two-color staining analysis (Fig. 3a) but are better resolved from background when a full six-color staining panel is used (Fig. 3b) . The expected naive phenotype of the CD90.1+ donor T cells is verified by their low expression of CD44. In this example, the total number of all cells harvested from the recipient mouse, as calculated in Box 1, is 2.97 Â 10 8 . The total number of donor TCR transgenic T cells in the mouse, as calculated in Box 2, is 2 Â 10 5 , which corresponds to a 'park' rate of about 20% of the original 10 6 transferred cells. This is at the upper end of the 5-20% park rate seen for most adoptive transfer experiments [9] [10] [11] .
The detection of low-frequency adoptively transferred cells following CD90.1 antibody-based enrichment is shown in the example in Figure 4 . As expected, CD90.1+ events are seen in the bound, but not unbound, fraction of the enrichment (Fig. 4a) . The total number of all cells in the bound fraction is 3.44 Â 10 6 (Box 1), which is within the range of 5 Â 10 5 -4 Â 10 6 total cells that we normally find in the bound fraction. Compared with the unbound fraction, the bound fraction contains a large number of highly autofluorescent cells that may contribute to background signal. Therefore, it is important to carefully exclude such cells when setting up gates to identify the donor T cells. The calculated total number of donor TCR transgenic T cells in this example is 74 (Box 2), which corresponds to 7.4% of the original 1,000 transferred cells. This is at the low end of the expected 5-20% park rate, but due to the extremely low concentration of cells in the transfer inoculum, the accuracy of cell-transfer doses in low-frequency adoptive transfer experiments is usually less than that of high-frequency experiments.
Tetramer-based enrichment analysis (Fig. 5) is similar to that of antibody-based enrichment. Tetramer-positive T-cell events are readily detected in the bound, but not unbound, fraction samples. The expected naive phenotype of the pMHC tetramerpositive T cells is verified by their low expression of CD44. As the epitope-specific T cells are polyclonal and exhibit a repertoire of TCR with varying affinities for pMHC, there is more variation in the staining intensities of the tetramer-positive cells (Fig. 5a) as compared with CD90.1+ T cells in antibody-enrichment experiments (Fig. 4a) . Therefore, the tetramer-positive gate 
